Liu Shaonan, Chen Jing, He Yihan, Wu Lei, Lai Jiaqi, Zuo Jinhong, Yang Lihong, Guo Xinfeng
EBM & Clinical Research Service Group, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
BMJ Open. 2017 Aug 11;7(8):e017099. doi: 10.1136/bmjopen-2017-017099.
Chinese medicine is commonly used to combine with pharmacotherapy for the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Six Chinese herb formulas involving Weijing decoction, Maxingshigan decoction, Yuebijiabanxia decoction, Qingqihuatan decoction, Dingchuan decoction and Sangbaipi decoction are recommended in Chinese medicine clinical guideline or textbook, to relieve patients with phlegm-heat according to Chinese syndrome differentiation. However, the comparative effectiveness among these six formulas has not been investigated in published randomised controlled trials. We plan to summarise the direct and indirect evidence for these six formulas combined with pharmacotherapy to determine the relative merits options for the management of AECOPD.
We will perform the comprehensive search for the randomised controlled trials to evaluate the effectiveness of six Chinese herb formulas recommended in Chinese medicine clinical guideline or textbook. The combination of pharmacotherapy includes bronchodilators, antibiotics and corticosteroids that are routinely prescribed for AECOPD. The primary outcome will be lung function, arterial blood gases and length of hospital stay. The data screening and extraction will be conducted by two different reviewers. The quality of RCT will be assessed according to the Cochrane handbook risk of bias tool. The Bayes of network meta-analysis (NMA) will be conducted with WinBUGS to compare the effectiveness of six formulas. We will also use the surface under the cumulative ranking curve (SUCRA) to obtain the comprehensive rank for these treatments.
This review does not require ethics approval and the results of NMA will be submitted to a peer-review journal.
PROSPERO (CRD42016052699).
中药常用于与药物治疗联合治疗慢性阻塞性肺疾病急性加重期（AECOPD）。中医临床指南或教科书中推荐了六种中药方剂，包括苇茎汤、麻杏石甘汤、越婢加半夏汤、清气化痰汤、定喘汤和桑白皮汤，根据中医辨证用于缓解痰热型患者。然而，这六种方剂之间的比较疗效尚未在已发表的随机对照试验中进行研究。我们计划总结这六种方剂联合药物治疗的直接和间接证据，以确定AECOPD管理的相对优势选择。
我们将全面检索随机对照试验，以评估中医临床指南或教科书中推荐的六种中药方剂的疗效。药物治疗组合包括AECOPD常规使用的支气管扩张剂、抗生素和皮质类固醇。主要结局将是肺功能、动脉血气和住院时间。数据筛选和提取将由两名不同的评审员进行。RCT的质量将根据Cochrane手册偏倚风险工具进行评估。将使用WinBUGS进行网络Meta分析（NMA）的贝叶斯分析，以比较六种方剂的疗效。我们还将使用累积排名曲线下面积（SUCRA）来获得这些治疗的综合排名。
本综述无需伦理批准，NMA的结果将提交给同行评审期刊。
PROSPERO（CRD42016052699）。
